Navigation Links
Semafore to Present at BIO CEO & Investor Conference
Date:2/8/2008

INDIANAPOLIS, Feb. 8 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today announced that Edward L. Jacobs, president and chief executive officer, and Ullrich Schwertschlag, M.D., Ph.D., chief medical officer, will present an update of the company's product development programs at 2:45 p.m. EST on Wednesday, Feb. 13, 2008, at the BIO CEO & Investor Conference in New York City.

The update will include information about Semafore's lead product candidate, SF1126, a targeted PI3 kinase inhibitor currently in Phase 1 clinical trials in solid tumors and multiple myeloma. The presentation will also include a review of the company's pipeline advancements and business development initiatives.

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is thought that inhibiting this pathway, via SF1126, could cause the resetting of sensitivity to approved agents and exhibit synergistic anticancer effects.

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PTEN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets. For more information see the company's Web site at http://www.SemaforePharma.com.

Contacts:

Corporate Media

Semafore Pharmaceuticals Inc. Russo Partners LLC

Bob Marsha
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical to present at BIO CEO & Investor Conference
2. Genomic Health to Present at BIO CEO & Investor Conference
3. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
4. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
5. Avicena Group to Present at 10th Annual BIO CEO & Investor Conference
6. Micromet to Present at Two Upcoming Investor Conferences
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Genelabs Technologies to Present at the BIO CEO & Investor Conference
9. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015   Decision Resources Group ... advantages of Otezla are its oral administration, alternative ... reported by surveyed rheumatologists. Otezla was the first ... treatment of active psoriatic arthritis in ... of care includes conventional oral treatments including disease-modifying ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 ... that uses next generation sequencing technology to empower cancer ... Storrer as chief executive officer. In his expanded ... responsible for all strategy, business expansion and worldwide operations ... served as Strand,s chairman and CEO since its founding ...
(Date:7/1/2015)... 2015  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced that the company will ... 5:45 p.m. EDT following its presentation of RVT-101 ... 2015 (AAIC). The event will ... Lawrence Friedhoff , Chief Development Officer, will ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan contest will ... barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 ... US$15,000 and a period of expert mentorship from a senior industry figure drawn from ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... ... the nation to offer Ultherapy™, a new non-surgical cosmetic procedure utilizing medical ultrasound. The Ulthera ... neck to lift and tighten the skin in a short, 30-minute procedure. , ... Seattle, WA (PRWEB) March 23, 2010 -- ...
... world,s leading analyst firm focused exclusively on startups and emerging markets, will be hosting a regional ,Pitch Slam, event in Berlin ... promote 100 top technology startups from around the world. , ... ... ...
... ... device experts join cell therapy consulting firm , ... Bellingham, WA (Vocus) March 18, 2010 -- Cell Therapy Group ... Haecker, PhD as Director, Regenerative Medicine Business, Daniel A. Segal, as Director, Stem Cell ...
Cached Biology Technology:Seattle Facial Plastic Surgeon Among First In The Nation To Offer Ultherapy™ 2Seattle Facial Plastic Surgeon Among First In The Nation To Offer Ultherapy™ 3Meet and Engage With Innovate!100 Semi-Finalists in Berlin on March 22 2Meet and Engage With Innovate!100 Semi-Finalists in Berlin on March 22 3Meet and Engage With Innovate!100 Semi-Finalists in Berlin on March 22 4Meet and Engage With Innovate!100 Semi-Finalists in Berlin on March 22 5Meet and Engage With Innovate!100 Semi-Finalists in Berlin on March 22 6Cell Therapy Group Announces Expansion of Consultants Roster in Regenerative Medicine 2Cell Therapy Group Announces Expansion of Consultants Roster in Regenerative Medicine 3Cell Therapy Group Announces Expansion of Consultants Roster in Regenerative Medicine 4
(Date:6/23/2015)... PALM BEACH GARDENS, Fla. , June ... of multi-factor identity management and authentication solutions, today ... Altus strong, multi-factor authentication solution.  The ... ease of use of the DigitalPersona Altus ... and biometric reader compatibility. In ...
(Date:6/17/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that Xiaomi, one of the world,s largest mobile ... ® family of capacitive touchscreen solutions and ... for its latest smartphones, the Xiaomi Mi Note ... in-cell display solutions and DDICs in discrete display ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... communicated that it will amount to at least 340 MSEK ... to the rapid increase in market growth and orders received ... communicated guidance that revenue for 2015 will exceed 1,500 MSEK ... to approximately 2,200 MSEK. Due to receipt of ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... of antibiotics has created strains of bacteria resistant to medication, ... deadly. But now a research team at the University of ... that scientists may be able to medically exploit. Biologists ... University, thought one key to stopping the bacteria may lie ...
... entry for the hummingbird explains that the bird,s flight ... helps the bird hover. But after conducting experiments with ... Riverside propose that the hovering hummingbird instead produces two trails ... that help generate the aerodynamic forces required for the bird ...
... Park Zoo rolls out several new educational initiatives designed ... and Collaboration. The center, an ambitious new endeavor made ... the Hurvis Charitable Foundation, is poised to address the ... nationwide to explore new approaches to effectively engage visitors ...
Cached Biology News:Superbugs may have a soft spot, after all 22 vortex trails with 1 stroke 22 vortex trails with 1 stroke 3Lincoln Park Zoo awarded $3 million leadership gift for education 2Lincoln Park Zoo awarded $3 million leadership gift for education 3
Ultra-sensitive, non-radioactive detection of rat Osteopontin...
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Biology Products: